Hi Dray’s, was the best/if not one of the best q&a sessions yet; more than half of the hour long sess was fielding questions as they arose; general quality of Qs was good.
Presentation wise; excellent slim down version - dot pointed punchy facts; each line was explained. In terms of near term market moving milestones - nothing we don’t know already, except for the the FDA tidbit mentioned above by grimloq, as per screenshot below:
more details to follow, but it’ll likely be a combined phase 1/2 approach over 24 month duration with intervention straight off the bat due to the rare disease cohort.
mum’s the word is the new strategy for PYC, something I endorse and respect as they are seeking to protect IP/long term game
Means we have to tuck these to the bottom drawer as we won’t been getting the lead up firework news that normally (over)excite punters - news flow will suit LT holders now.
The most interesting to take for me was that they got beat by Roche for one of their potential assets during the IP claim/challenge. Seem like we lost 18 months of work/investment there and can sense the disappointment, but the fact that we are playing in the same cell type as a US$300B+ pharma titan speaks untold volumes - The titan was operating in stealth mode hence zero existing literature awareness.
(20min delay)